Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804

Q2 FY22 results · Jul–Sep 2021

Aurobindo Pharma reported revenue from operations of ₹5,941.92 crore (down 8.4% from Q2 FY21) and net profit of ₹696.71 crore (down 13.5% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY22	Q2 FY21	YoY	Q1 FY22	QoQ
Revenue from operations	5,941.92	6,483.44	−8.4%	5,701.98	+4.2%
Other income	96.58	53.75	+79.7%	81.31	+18.8%
Total income	6,038.50	6,537.19	−7.6%	5,783.29	+4.4%
Profit before share of associates & JVs and tax	978.67	1,213.51	−19.4%	1,026.71	−4.7%
Share of profit/(loss) of associates & JVs	(11.05)	(20.53)		(9.00)
Net profit for the period	696.71	805.65	−13.5%	769.97	−9.5%
Attributable to shareholders of the company	696.99	806.23	−13.5%	769.97	−9.5%
EPS, basic (₹)	11.89	13.75	−13.5%	13.14	−9.5%
Net margin (%)	11.7	12.4		13.5

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY22	Q2 FY21	YoY	Q1 FY22	QoQ
Revenue from operations	2,883.18	4,524.34	−36.3%	2,893.75	−0.4%
Other income	82.37	48.62	+69.4%	27.03	+204.7%
Total income	2,965.55	4,572.96	−35.2%	2,920.78	+1.5%
Profit before tax	320.48	1,129.20	−71.6%	335.05	−4.3%
Net profit for the period	197.68	801.54	−75.3%	215.07	−8.1%
EPS, basic (₹)	3.37	13.68	−75.4%	3.67	−8.2%
Net margin (%)	6.9	17.7		7.4

Consolidated

Filed with BSE: 09 Nov 2021, 15:54 IST
Board meeting: 08 Nov 2021
Period: 01 Jul 2021 to 30 Sep 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 09 Nov 2021, 15:54 IST
Board meeting: 08 Nov 2021
Period: 01 Jul 2021 to 30 Sep 2021
Review status: Unaudited
Source: XBRL filing on BSE